Methylglyoxal-augmented manuka honey as a topical
anti–Staphylococcus aureus biofilm agent: safety and efficacy in an in vivo
model
Article first published online: 10 JAN 2014
Background
Bacterial biofilms are thought to contribute to
recalcitrance in chronic rhinosinusitis (CRS) patients. Manuka honey (MH) and
its active component methylglyoxal (MGO) have demonstrated antibiofilm activity
in vitro. This study evaluated the safety and efficacy of these agents in an in
vivo model.
Methods
To assess safety, ovine frontal sinuses were flushed twice
daily for 14 days. In each sheep, 1 sinus was flushed with a panel of MGO
concentrations ranging from 0.5 to 7.2 mg/mL alone and flushed with a panel of
with 16.5% wt/vol MH enriched with MGO at the same range of concentrations
(0.5–7.2 mg/mL; designated MH/MGO). Contralateral sinuses were flushed with
saline control. Tissue morphology was assessed histologically and with scanning
electron microscopy. Efficacy was tested by developing Staphylococcus aureus
biofilms in sheep sinuses. Twice-daily irrigation for 5 days was commenced with
either saline, MGO (0.5–3.6 mg/mL) alone, or MH/MGO (with 0.5–3.6 mg/mL MGO).
Biofilm biomass was compared between the groups (n = 4) using LIVE/DEAD
BacLight staining and confocal scanning laser microscopy.
Results
The results of the safety assessment, for normal sinuses
treated with MGO alone or with MH/MGO (≤1.8 mg/mL) showed normal
pseudostratified epithelium and cilia structure; however, higher concentrations
caused cilia denudation and squamous metaplasia. As for efficacy, when compared
to saline flush, treatment with MH/MGO at 0.9 mg/mL (0.608 ± 0.110 vs 0.316 ±
0.197 μm3/μm2, respectively; p = 0.015) and 1.8 mg/mL (0.676 ± 0.079 vs 0.114 ±
0.033 μm3/μm2, respectively; p = 0.001) significantly reduced biofilm biomass.
Conclusion
Sinus irrigation with MH/MGO at MGO concentrations between
0.9 and 1.8 mg/mL is both safe to mucosa and efficacious against S. aureus biofilm.
MH/MGO irrigation could represent a viable treatment option for recalcitrant
CRS.
No comments:
Post a Comment